The atezolizumab market comprises monoclonal antibodies used for treatment of various types of cancers including urothelial carcinoma, non-small cell lung cancer, and triple-negative breast cancer. Atezolizumab functions by inhibiting the programmed death-ligand 1 receptor (PD-L1) and restoring the anti-tumor immune response. It provides an effective treatment option with relatively fewer side...